Reyon Pharmaceutical Co Ltd (102460.KS)
REYON Pharmaceutical Co., Ltd. manufactures and sells medicines. The company offers its products under the areas of adrenal corticosteroides; angiotensin II receptor antagonists; antibiotics; anticholinergics; antiemetic; antihypertensives; anti-inflammatory enzymes; antilipidemic, antirheumatic, and oral hypoglycemic agents; anti-peptic ulcer; antispasmodics; benign prostatic hypertrophy; cough and cold remedies; cardiac stimulant; genitourinary smooth muscle relaxants; hemostatics; immunosuppressants; rheumatoid arthritis; local anesthetics; migraine drugs; miscellaneous cardiovascular system drugs; neuromuscular disorder related drugs; nootropics and neurotonics; NSAIDs; respiratory stimulants; skeletal muscle relaxants; and vasodilators. It also develops VM202RY, a vascular neurological disease, etc. gene therapy drug, which is in Phase II clinical trial to treat coronary artery disease, chronic non-healing diabetic/ischemic ulcers, diabetic neuropathy, and amyotrophic lateral sclerosis; VM206RY, anti-cancer gene therapy, which is under Phase I clinical trials for treatment of breast cancer; RY103 [NS101], therapeutics antibody for Alzheimer; and RY104, a gene therapy to treat age-related macular degeneration, as well as BIO-101, a HBV gene vaccine, which is in preclinical studies for hepatitis B; RY105, gene therapy to treat liver fibrosis; GB102, for treatment of chronic kidney and coronary artery disease; RY110 which is an iPSC-derived NK cell therapy for solid tumors; RY108, an antifungal drug which is under preclinical study. In addition, the company engages in the research of RY106/RY107, a mRNA-based virus vaccine and gene therapy for anti-virus and rare genetic diseases; and RY109 which is a pDNA-based cancer vaccine for treatment of Ovarian cancer. REYON Pharmaceutical Co., Ltd. was founded in 1955 and is headquartered in Seoul, South Korea.
Company Info
Highlights
₩201.75B
₩148.04B
₩67.77B
₩9,830.00 - ₩18,650.00
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
Reyon Pharmaceutical Co Ltd (102460.KS) returned -14.33% year-to-date (YTD) and -23.18% over the past 12 months. Over the past 10 years, 102460.KS returned -7.33% annually, underperforming the S&P 500 benchmark at 10.85%.
102460.KS
-14.33%
-1.87%
-20.00%
-23.18%
-26.49%
-3.34%
-7.33%
^GSPC (Benchmark)
0.51%
3.96%
-2.00%
12.02%
12.68%
14.19%
10.85%
Monthly Returns
The table below presents the monthly returns of 102460.KS, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -0.70% | -6.35% | -6.11% | 1.34% | -3.17% | -14.33% | |||||||
| 2024 | -8.34% | -1.39% | 2.01% | -9.64% | 3.92% | -4.82% | 2.79% | -0.50% | -0.36% | 17.21% | -15.54% | -6.62% | -22.37% |
| 2023 | -9.79% | -2.71% | -5.63% | 3.63% | -3.98% | -6.67% | -5.29% | 3.42% | -2.45% | -11.31% | 5.32% | 12.37% | -22.87% |
| 2022 | -19.83% | -2.46% | 7.55% | -6.35% | 0.54% | -20.25% | 16.70% | -9.16% | -19.54% | 0.26% | 2.60% | 10.65% | -38.68% |
| 2021 | -13.12% | -6.77% | -5.03% | 19.41% | 72.91% | 37.61% | 5.80% | 3.13% | 0.00% | 5.31% | -28.29% | -10.02% | 62.04% |
| 2020 | -13.12% | -10.43% | -12.45% | 27.52% | -1.08% | 20.00% | -1.82% | 29.32% | 5.01% | -15.23% | 23.86% | -1.45% | 42.28% |
| 2019 | 9.35% | 20.72% | 5.72% | -1.80% | -14.70% | 0.62% | -12.84% | -5.61% | -4.46% | 18.68% | -2.95% | 10.57% | 17.73% |
| 2018 | 15.58% | -10.46% | 15.06% | -2.34% | -7.60% | -13.64% | -1.25% | 13.20% | -6.28% | -21.53% | 5.49% | -16.49% | -32.80% |
| 2017 | -4.12% | 6.09% | -2.36% | -4.50% | 4.17% | -0.00% | -4.17% | 9.07% | 5.16% | 14.24% | -6.19% | -16.03% | -2.28% |
| 2016 | 4.35% | -16.81% | -3.95% | -4.43% | 10.10% | -0.15% | 7.83% | -11.31% | -2.36% | -17.74% | 11.37% | 3.73% | -22.27% |
| 2015 | -2.39% | 6.86% | 12.39% | 10.61% | 27.68% | 21.68% | -15.08% | -7.13% | -11.90% | 23.76% | 4.14% | 1.39% | 82.89% |
| 2014 | 12.29% | 2.99% | -7.25% | -1.04% | 6.05% | 25.81% | -2.76% | 16.84% | -12.33% | -5.35% | -3.77% | -7.99% | 18.23% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of 102460.KS is 18, meaning it’s performing worse than 82% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Reyon Pharmaceutical Co Ltd (102460.KS) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Reyon Pharmaceutical Co Ltd provided a 0.00% dividend yield over the last twelve months, with an annual payout of ₩0.00 per share.
| Period | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | ₩0.00 | ₩0.00 | ₩150.00 | ₩150.00 | ₩250.00 | ₩200.00 | ₩343.14 | ₩490.20 | ₩343.14 | ₩263.95 | ₩226.24 | ₩188.54 |
Dividend yield | 0.00% | 0.00% | 0.91% | 0.69% | 0.70% | 0.90% | 2.19% | 3.60% | 1.63% | 1.20% | 0.79% | 1.20% |
Monthly Dividends
The table displays the monthly dividend distributions for Reyon Pharmaceutical Co Ltd. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | |||||||
| 2024 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 |
| 2023 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩150.00 | ₩150.00 |
| 2022 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩150.00 | ₩150.00 |
| 2021 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩250.00 | ₩250.00 |
| 2020 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩200.00 | ₩200.00 |
| 2019 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩343.14 | ₩343.14 |
| 2018 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩490.20 | ₩490.20 |
| 2017 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩343.14 | ₩343.14 |
| 2016 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩263.95 | ₩263.95 |
| 2015 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩226.24 | ₩226.24 |
| 2014 | ₩188.54 | ₩188.54 |
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Reyon Pharmaceutical Co Ltd. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Reyon Pharmaceutical Co Ltd was 85.73%, occurring on Apr 8, 2025. The portfolio has not yet recovered.
The current Reyon Pharmaceutical Co Ltd drawdown is 84.38%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -85.73% | Jul 9, 2021 | 918 | Apr 8, 2025 | — | — | — |
| -77.82% | Jul 6, 2015 | 1156 | Mar 19, 2020 | 286 | May 17, 2021 | 1442 |
| -39.33% | Feb 20, 2012 | 67 | May 25, 2012 | 90 | Oct 5, 2012 | 157 |
| -38.64% | Jul 14, 2014 | 126 | Jan 16, 2015 | 83 | May 20, 2015 | 209 |
| -37.52% | Apr 29, 2013 | 39 | Jun 25, 2013 | 252 | Jul 4, 2014 | 291 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Reyon Pharmaceutical Co Ltd over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Reyon Pharmaceutical Co Ltd, comparing actual results with analytics estimates.
Valuation
The Valuation section provides an overview of how Reyon Pharmaceutical Co Ltd is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for 102460.KS compared to other companies in the Drug Manufacturers - Specialty & Generic industry. 102460.KS currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for 102460.KS relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, 102460.KS has a P/S ratio of 1.4. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for 102460.KS in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, 102460.KS has a P/B value of 0.8. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |